Lifesci Capital Predicts Opus Genetics FY2025 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for Opus Genetics in a research note issued on Thursday, February 12th. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($0.65) per share for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. Lifesci Capital also issued estimates for Opus Genetics’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.48) EPS.

A number of other brokerages also recently weighed in on IRD. Brookline Capital Acquisition raised Opus Genetics to a “strong-buy” rating in a research report on Monday, December 1st. Wedbush assumed coverage on shares of Opus Genetics in a research report on Wednesday, October 29th. They issued an “outperform” rating and a $8.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. B. Riley Financial assumed coverage on shares of Opus Genetics in a research report on Wednesday, December 10th. They set a “buy” rating and a $9.00 target price for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Opus Genetics in a research report on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $7.75.

Opus Genetics Trading Up 7.4%

Shares of NASDAQ:IRD opened at $3.64 on Monday. The company has a market capitalization of $251.01 million, a PE ratio of -1.94 and a beta of 0.58. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.18. Opus Genetics has a 12-month low of $0.65 and a 12-month high of $3.70. The business’s fifty day simple moving average is $2.39 and its 200-day simple moving average is $1.93.

Insider Buying and Selling

In related news, Director Fighting Blindness Foundation sold 4,000,000 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the completion of the transaction, the director owned 5,492,171 shares of the company’s stock, valued at $11,808,167.65. This trade represents a 42.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cam Gallagher acquired 83,000 shares of Opus Genetics stock in a transaction on Monday, December 29th. The shares were bought at an average price of $1.97 per share, with a total value of $163,510.00. Following the purchase, the director directly owned 83,000 shares in the company, valued at approximately $163,510. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its holdings in Opus Genetics by 42.9% in the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after buying an additional 1,435,407 shares during the last quarter. BIOS Capital Management LP boosted its stake in shares of Opus Genetics by 270.1% in the second quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock worth $3,462,000 after acquiring an additional 2,688,180 shares during the last quarter. Mink Brook Asset Management LLC increased its position in shares of Opus Genetics by 34.5% during the fourth quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock worth $3,348,000 after purchasing an additional 427,684 shares in the last quarter. Vanguard Group Inc. raised its stake in Opus Genetics by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock valued at $2,214,000 after purchasing an additional 349,825 shares during the last quarter. Finally, Opaleye Management Inc. raised its position in shares of Opus Genetics by 3.8% in the second quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company’s stock valued at $1,149,000 after buying an additional 45,000 shares during the last quarter. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.